Research on er+ breast cancer suggests that esr1 status and the choice of cdk4/6 inhibitors may influence clonal selection. A study appears to have investigated how esr1 mutations impact resistance to cdk4/6 inhibitors. The findings of the study are being reported, although the specifics of the research and its conclusions are not entirely clear.